Accelerate Diagnostics, Inc. (NASDAQ:AXDX – Get Free Report) CEO Jack Phillips sold 26,545 shares of Accelerate Diagnostics stock in a transaction on Friday, April 12th. The stock was sold at an average price of $0.86, for a total transaction of $22,828.70. Following the completion of the transaction, the chief executive officer now directly owns 129,726 shares in the company, valued at $111,564.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Jack Phillips also recently made the following trade(s):
- On Thursday, April 4th, Jack Phillips sold 15,887 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $0.88, for a total transaction of $13,980.56.
- On Thursday, February 1st, Jack Phillips sold 494 shares of Accelerate Diagnostics stock. The stock was sold at an average price of $1.30, for a total transaction of $642.20.
Accelerate Diagnostics Price Performance
NASDAQ:AXDX traded down $0.08 during mid-day trading on Wednesday, hitting $0.74. The company’s stock had a trading volume of 115,691 shares, compared to its average volume of 120,337. Accelerate Diagnostics, Inc. has a 1 year low of $0.73 and a 1 year high of $11.90. The stock has a market cap of $16.01 million, a price-to-earnings ratio of -0.15 and a beta of 0.52. The business’s fifty day moving average is $1.02 and its two-hundred day moving average is $3.23.
Institutional Inflows and Outflows
Wall Street Analysts Forecast Growth
Several research firms have issued reports on AXDX. Craig Hallum cut their price target on shares of Accelerate Diagnostics from $2.00 to $1.00 and set a “hold” rating on the stock in a report on Monday, April 1st. StockNews.com started coverage on shares of Accelerate Diagnostics in a report on Friday, April 12th. They set a “hold” rating on the stock. Finally, William Blair reissued an “outperform” rating on shares of Accelerate Diagnostics in a report on Tuesday, April 2nd.
View Our Latest Stock Analysis on Accelerate Diagnostics
About Accelerate Diagnostics
Accelerate Diagnostics, Inc, an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms.
Featured Articles
- Five stocks we like better than Accelerate Diagnostics
- What Are Dividends? Buy the Best Dividend Stocks
- United Airlines Soars on Earnings Beat
- Most Volatile Stocks, What Investors Need to Know
- J.B. Hunt Hits the Skids: Lower Prices to Come
- Procter & Gamble (NYSE:PG) Pulls Back After Shaky Guidance
- Predicting a Bear Market: 7 Signs and Why it’s Tough to Do
Receive News & Ratings for Accelerate Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accelerate Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.